Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent

Kirihara T., Taniguchi T., Yamamura K., Iwamura R., Yoneda K., Odani-Kawabata N., Shimazaki A., Matsugi T., Shams N., Zhang J.-Z.

2018
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Glaucoma
Technology

Pharmacology

Affiliations

R & D Division, Santen Pharmaceutical Co., Ltd, Grand Front Osaka Tower A, Kita-Ku, Osaka, Japan; R & D Division, Santen Pharmaceutical Co., Ltd, Ikoma-shi, Nara, Japan; Corporate Research & Development, Ube Industries, Ltd, Ube, Yamaguchi, Japan; R & D Division, Santen Inc, Emeryville, CA, United States

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications